The Medicines Company Agrees to Divest its Hemostasis Portfolio to Mallinckrodt plc

The Medicines Company Agrees to Divest its Hemostasis Portfolio to Mallinckrodt plc

News

On December 18, The Medicines Company (NASDAQ:MDCO) announced that it entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company's global portfolio of three hemostasis products—RECOTHROM® Thrombin topical (Recombinant), PreveLeak™, and RAPLIXA™ (fibrin sealant)—for a total potential consideration of up to $410 million.

The WilmerHale team representing The Medicines Company was led by Partner Joe Conahan and included Senior Associate Michael Welhouse and Associate Mark Nylen (corporate), as well as Partners Steve Barrett (IP), Robert Burke (tax), Scott Kilgore (labor and employment), Bruce Manheim (regulatory), Hartmut Schneider and Special Counsel Jeffrey Ayer (antitrust).   

The formal press release can be found on www.themedicinescompany.com